Nature Communications (Sep 2020)
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
- Rong Wang,
- Tadaaki Yamada,
- Kenji Kita,
- Hirokazu Taniguchi,
- Sachiko Arai,
- Koji Fukuda,
- Minoru Terashima,
- Akihiko Ishimura,
- Akihiro Nishiyama,
- Azusa Tanimoto,
- Shinji Takeuchi,
- Koshiro Ohtsubo,
- Kaname Yamashita,
- Tomoyoshi Yamano,
- Akihiro Yoshimura,
- Koichi Takayama,
- Kyoichi Kaira,
- Yoshihiko Taniguchi,
- Shinji Atagi,
- Hisanori Uehara,
- Rikinari Hanayama,
- Isao Matsumoto,
- Xujun Han,
- Kunio Matsumoto,
- Wei Wang,
- Takeshi Suzuki,
- Seiji Yano
Affiliations
- Rong Wang
- Division of Medical Oncology, Cancer Research Institute, Kanazawa University
- Tadaaki Yamada
- Division of Medical Oncology, Cancer Research Institute, Kanazawa University
- Kenji Kita
- Division of Medical Oncology, Cancer Research Institute, Kanazawa University
- Hirokazu Taniguchi
- Division of Medical Oncology, Cancer Research Institute, Kanazawa University
- Sachiko Arai
- Division of Medical Oncology, Cancer Research Institute, Kanazawa University
- Koji Fukuda
- Division of Medical Oncology, Cancer Research Institute, Kanazawa University
- Minoru Terashima
- Division of Functional Genomics, Cancer Research Institute, Kanazawa University Kanazawa
- Akihiko Ishimura
- Division of Functional Genomics, Cancer Research Institute, Kanazawa University Kanazawa
- Akihiro Nishiyama
- Division of Medical Oncology, Cancer Research Institute, Kanazawa University
- Azusa Tanimoto
- Division of Medical Oncology, Cancer Research Institute, Kanazawa University
- Shinji Takeuchi
- Division of Medical Oncology, Cancer Research Institute, Kanazawa University
- Koshiro Ohtsubo
- Division of Medical Oncology, Cancer Research Institute, Kanazawa University
- Kaname Yamashita
- Division of Medical Oncology, Cancer Research Institute, Kanazawa University
- Tomoyoshi Yamano
- Department of Immunology, Graduate School of Medicine, Kanazawa University
- Akihiro Yoshimura
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
- Koichi Takayama
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
- Kyoichi Kaira
- Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University
- Yoshihiko Taniguchi
- Department of Thoracic Oncology, National Hospital Organization Kinki-chuo Chest Medical Center
- Shinji Atagi
- Department of Thoracic Oncology, National Hospital Organization Kinki-chuo Chest Medical Center
- Hisanori Uehara
- Division of Pathology, Tokushima University Hospital
- Rikinari Hanayama
- Nano Life Science Institute, Kanazawa University
- Isao Matsumoto
- Department of Thoracic, Cardiovascular and General Surgery, Kanazawa University
- Xujun Han
- Division of Medical Oncology, Cancer Research Institute, Kanazawa University
- Kunio Matsumoto
- Nano Life Science Institute, Kanazawa University
- Wei Wang
- Department of Radiation Oncology, Nanfang Hospital, Southern Medical University
- Takeshi Suzuki
- Division of Functional Genomics, Cancer Research Institute, Kanazawa University Kanazawa
- Seiji Yano
- Division of Medical Oncology, Cancer Research Institute, Kanazawa University
- DOI
- https://doi.org/10.1038/s41467-020-18442-4
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 14
Abstract
Cancer cells develop resistance to tyrosine kinase inhibitors targeting EGFR. Here, the authors explore the mechanism of resistance to one such inhibitor - osimertinib - and find that resistance is caused by increased expression and activation of the IGF1 receptor and subsequent activation of the donwstream signalling pathway.
